公开(公告)号：US20200255528A1

公开(公告)日：2020-08-13

申请号：US16814627

申请日：2020-03-10

Applicant: Five Prime Therapeutics, Inc.

Inventor： Charles KAPLAN ,  Derrick HOUSER ,  Luis BORGES ,  Gloria BRATTICH ,  David BELLOVIN ,  Felicia KEMP ,  Majid GHODDUSI ,  Nels P. NIELSON ,  Kathy MILLER ,  Maike SCHMIDT

IPC: C07K16/28 ,  G01N33/574 ,  A61P35/00

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

公开(公告)号：US20230052212A1

公开(公告)日：2023-02-16

申请号：US17818256

申请日：2022-08-08

Applicant: FIVE PRIME THERAPEUTICS, INC.

Inventor： Kristen PIERCE ,  Janine POWERS ,  Servando PALENCIA ,  Robert SIKORSKI ,  Majid GHODDUSI ,  Kartik KRISHNAN

IPC: C07K16/28 ,  G01N33/50 ,  G01N33/574 ,  C07K16/30

Abstract: Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.

公开(公告)号：US20210079096A1

公开(公告)日：2021-03-18

申请号：US17006670

申请日：2020-08-28

Applicant: Five Prime Therapeutics, Inc.

Inventor： Charles KAPLAN ,  Alessandro PALUMBO ,  Kathy MILLER ,  Hangil PARK ,  Nerissa MENDOZA ,  Majid GHODDUSI

IPC: C07K16/28 ,  G01N33/574

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4. The anti-B7-H4 antibodies or antigen-binding fragments thereof are useful, for example in detecting B7-H4. Immunohistochemistry (IHC) can be used to detect B7-H4 The present disclosure also provides methods for treating cancer wherein increased B7-H4 has been detected, by administering a therapeutic anti-B7-H4 antibody or antigen-binding fragment thereof.